Medical Condition News

RSS

Positive results from Boston Scientific's Lotus Aortic Valve System trial

Boston Scientific Corporation announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus Aortic Valve System in patients with severe aortic valve disease.

16 May 2012

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.

16 May 2012

Exendin-4 drug effectively suppresses craving for food

A drug made from the saliva of the Gila monster lizard is effective in reducing the craving for food. Researchers at the Sahlgrenska Academy, University of Gothenburg, have tested the drug on rats, who after treatment ceased their cravings for both food and chocolate.

16 May 2012

Link between dietary supplements and increased risk of cancer

Beta-carotene, selenium and folic acid - taken up to three times their recommended daily allowance, these supplements are probably harmless. But taken at much higher levels as some supplement manufacturers suggest, these three supplements have now been proven to increase the risk of developing a host of cancers.

16 May 2012

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.

16 May 2012

BiO2 Medical receives CE Mark approval for Angel Catheter to prevent PE

BiO2 Medical, Inc. a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, announced today that it has received CE Mark approval for the Angel Catheter, a Nitinol Inferior Vena Cava (IVC) filter, permanently attached to a central venous catheter (CVC) for the use of preventing Pulmonary Embolism (PE) in critically ill patients.

16 May 2012

Novelos completes I-131-CLR1404 Phase 1b trial on advanced solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the first cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.

16 May 2012

Svelte completes enrollment in DIRECT drug-eluting stent study

Svelte Medical Systems today announced completion of enrollment in the DIRECT (Direct Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study conducted at four investigational sites in New Zealand.

15 May 2012

Asymptomatic patients can benefit from ExE after coronary revascularization

Asymptomatic patients who undergo treadmill exercise echocardiography (ExE) after coronary revascularization may be identified as being at high risk but those patients do not appear to have more favorable outcomes with repeated revascularization, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication. The article is part of the journal's Less is More series.

15 May 2012

Cyclophosphamide drug makes the bone marrow more tumor-friendly

Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily.

15 May 2012

Harvard cardiologist receives Cedars-Sinai’s Corday Prize in Heart Research

Cedars-Sinai Heart Institute is honoring Eugene Braunwald, MD, Distinguished Hersey Professor of Medicine at Harvard Medical School, with The Eliot Corday, MD, International Prize in Heart Research. The Corday Prize has been established to recognize physicians and scientists conducting groundbreaking research that has, or very likely will, change the practice of heart medicine. Braunwald is the inaugural recipient of the annual prize.

15 May 2012

Study demonstrates long-term effectiveness of classroom-based drug prevention program

A new study presented at an international conference in Texas demonstrates the long-term effectiveness of a classroom-based prevention program targeting teen drug use.

15 May 2012

New Liquid ready-to-use Tumour Marker Control available now from Randox

The new Randox Acusera multi-analyte Liquid Tumour Marker Control covers a total of 15 commonly tested and esoteric cancer antigens and tumour markers. The addition of assayed target values enables laboratories to effectively monitor both accuracy and precision.

From Randox Laboratories Ltd. 15 May 2012

Many men do not protect their skin from sun exposure

As everyone knows, growing older brings an increased number of health concerns. In fact, dermatologists warn that men older than 50 have an increased risk of developing melanoma - the deadliest form of skin cancer.

15 May 2012

Health care system should provide proactive interventions to prevent depression

Major depressive episodes can be prevented, and to help ensure that they are, the health care system should provide routine access to depression-prevention interventions, just as patients receive standard vaccines, according to a new article co-authored by UCSF researcher Ricardo F. Mu-oz, PhD.

15 May 2012

First study to track movement of individuals with dementia until death

A new study from the Regenstrief Institute and Indiana University has found that, at time of death, individuals with dementia are more likely to be living at home than in a nursing home. This contradicts the commonly held view that most individuals with dementia in the United States eventually move to nursing homes and die there.

15 May 2012

Persistent Systems, TGen collaborate on Bio4D software program

Persistent Systems, the leader in outsourced software product development (OPD) services, and the Translational Genomics Research Institute (TGen) today announced that they are developing a high-quality biospecimen management system called Bio4D.

15 May 2012

Significant breakthrough in understanding the cause of bile duct cancer

A team of international scientists has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct cancers, researchers are paving the way for better understanding of how bile duct cancers develop. Their discovery is published online in Nature Genetics.

15 May 2012

Human embryonic stem cells can be used to grow bone tissue grafts

Dr. Darja Marolt, an Investigator at The New York Stem Cell Foundation (NYSCF) Laboratory, is lead author on a study showing that human embryonic stem cells can be used to grow bone tissue grafts for use in research and potential therapeutic application. Dr. Marolt conducted this research as a post-doctoral NYSCF - Druckenmiller Fellow at Columbia University in the laboratory of Dr. Gordana Vunjak-Novakovic.

15 May 2012

Study identifies biomarkers that can predict recurrence of prostate cancer

Alterations to the "on-off" switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches, a Mayo Clinic study has found.

15 May 2012